Alivus Life Sciences · NSE: ALIVUS · BSE: 543322
Q3 FY23 results · Oct–Dec 2022
Alivus Life Sciences reported revenue from operations of ₹540.73 crore (up 3.5% from Q3 FY22) and net profit of ₹104.99 crore (up 1.2% from Q3 FY22) for Q3 FY23 (Oct–Dec 2022), on a standalone basis.
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 540.73 | 522.50 | +3.5% | 509.30 | +6.2% |
| Other income | 6.61 | 3.53 | +87.0% | 10.02 | −34.1% |
| Total income | 547.34 | 526.03 | +4.1% | 519.32 | +5.4% |
| Profit before tax | 141.14 | 139.80 | +1.0% | 143.59 | −1.7% |
| Net profit for the period | 104.99 | 103.71 | +1.2% | 106.88 | −1.8% |
| EPS, basic (₹) | 8.57 | 8.65 | −0.9% | 8.72 | −1.7% |
| Net margin (%) | 19.4 | 19.8 | 21.0 |
Standalone
- Filed with BSE
- 27 Jan 2023, 16:44 IST
- Board meeting
- 27 Jan 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE